tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Haemonetics price target lowered to $68 from $84 at Needham

Needham analyst Mike Matson lowered the firm’s price target on Haemonetics (HAE) to $68 from $84 and keeps a Buy rating on the shares. The company’s Q1 topped estimates but it maintained prior guidance despite the beat, the analyst tells investors in a research note. The firm says the the stock is trading down 21% given deterioration in Haemonetics’ Interventional Technologies business.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1